Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have received an average rating of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $11.13.

A number of brokerages have weighed in on STRO. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Sutro Biopharma in a research report on Monday, November 18th. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Sutro Biopharma in a research note on Tuesday, December 10th. Wells Fargo & Company cut their price objective on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Finally, JMP Securities restated a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a report on Wednesday, December 11th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can purchased a new stake in Sutro Biopharma during the third quarter worth approximately $2,852,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Sutro Biopharma during the 3rd quarter worth approximately $1,512,000. Barclays PLC boosted its holdings in shares of Sutro Biopharma by 385.3% in the 3rd quarter. Barclays PLC now owns 273,019 shares of the company’s stock valued at $944,000 after buying an additional 216,757 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Sutro Biopharma by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock valued at $6,426,000 after buying an additional 132,015 shares during the last quarter. Finally, Thrivent Financial for Lutherans acquired a new stake in Sutro Biopharma during the 4th quarter worth $178,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Stock Down 10.1 %

NASDAQ:STRO opened at $1.79 on Tuesday. The company has a market capitalization of $147.60 million, a P/E ratio of -1.11 and a beta of 1.15. Sutro Biopharma has a 52 week low of $1.67 and a 52 week high of $6.13. The stock’s fifty day moving average is $2.05 and its two-hundred day moving average is $3.14.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.